Compare Recursion Pharmaceuticals Inc (RXRX) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Tyson Foods, Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B), while Tyson Foods, Inc. trades at $56.65 (market cap $20.11B). The key difference: Tyson Foods, Inc. is far larger — about 11.3× Recursion Pharmaceuticals Inc's market cap, and Tyson Foods, Inc. pays a 3.57% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | TSN | |
|---|---|---|
Market Cap | $1.78B | $20.11B |
Sector | Health | Consumer Staples |
52-Week High | $6.79 | $68.75 |
52-Week Low | $2.84 | $50.72 |
Enterprise Value | $1.30B | $27.37B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Tyson Foods (TSN) trades at $58.04, down 0.85% on the day, with a bearish technical signal and mixed earnings history. The company reported Q3 2026 EPS of $0.99, beating estimates, but revenue trends are pressured by beef segment losses. Valuation metrics show a P/E of 35.83 and P/S of 0.37, with a consensus analyst price target of $68.50. Recent news highlights debt tender offers and a maintained quarterly dividend of $0.51.
The outlook is cautious due to persistent beef margin challenges, though chicken and prepared foods provide stability. Investment appeal lies in the discounted valuation and dividend yield, but risks include volatile input costs and competitive pressures. Analyst sentiment is divided, with 50% buy ratings but bearish technical indicators suggesting near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
